Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Changes in magnetic resonance imaging scores and ventilation inhomogeneity in children with cystic fibrosis pulmonary exacerbations

Hartmut Grasemann, Pierluigi Ciet, Reshma Amin, Nancy McDonald, Michelle Klingel, Harm A.W.M. Tiddens, Felix Ratjen, Lars Grosse-Wortmann
European Respiratory Journal 2017 50: 1700244; DOI: 10.1183/13993003.00244-2017
Hartmut Grasemann
1Division of Respiratory Medicine, Dept of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
2Program in Physiology and Experimental Medicine, Research Institute, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hartmut.grasemann@sickkids.ca
Pierluigi Ciet
3Dept of Pediatric Pulmonology, Erasmus MC/Sophia Children's Hospital, Rotterdam, The Netherlands
4Dept of Radiology and Nuclear Medicine, Erasmus MC/Sophia Children's Hospital, Rotterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reshma Amin
1Division of Respiratory Medicine, Dept of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nancy McDonald
1Division of Respiratory Medicine, Dept of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michelle Klingel
2Program in Physiology and Experimental Medicine, Research Institute, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Harm A.W.M. Tiddens
3Dept of Pediatric Pulmonology, Erasmus MC/Sophia Children's Hospital, Rotterdam, The Netherlands
4Dept of Radiology and Nuclear Medicine, Erasmus MC/Sophia Children's Hospital, Rotterdam, The Netherlands
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Felix Ratjen
1Division of Respiratory Medicine, Dept of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
2Program in Physiology and Experimental Medicine, Research Institute, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lars Grosse-Wortmann
5Labatt Family Heart Centre, Dept of Pediatrics and Dept of Diagnostic Imaging, Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Resolution of mucus plugging may explain worsening LCI during pulmonary exacerbation treatment in children with CF http://ow.ly/LTLm30dp6hS

To the Editor:

Acute pulmonary exacerbations (aPEs) in patients with cystic fibrosis (CF) often result in incomplete recovery of lung function despite treatment, and are associated with lung function decline over time [1, 2]. Monitoring is therefore important to detect aPEs early and to track treatment responses. Recent studies testing pulmonary function with multiple breath washout (MBW) have shown that the lung clearance index (LCI), the main outcome measure of MBW, is a sensitive tool to measure early changes in the CF lung [3, 4]. However, the potential role of MBW and LCI in more advanced CF lung disease is currently unclear. In fact, a recent study demonstrated heterogeneous responses in LCI, with a significant proportion of patients with CF showing worsening of LCI with treatment for aPEs [5]. Resolution of mucus plugging, resulting in recruitment of poorly ventilated areas of the lung to MBW, would potentially explain the discordant changes in pulmonary function testing by spirometry and LCI with treatment.

Magnetic resonance imaging (MRI) of the chest is increasingly used to detect both early changes in the CF lung as well as improvement in response to treatment of aPE, including mucus plugging [4, 6]. To assess whether improvement in mucus plugging can explain the variability in LCI response in patients with CF treated for aPE, we therefore performed parallel measurements of both MRI and LCI in patients before and after treatment of aPE with intravenous antibiotics.

The study was approved by the research ethics board of the Hospital for Sick Children in Toronto, ON, Canada. Participants were recruited between May 2011 and November 2012 from children presenting to the CF outpatient department with clinical signs of a CF aPE requiring hospital admission and treatment with intravenous antibiotics. Following informed written consent from patients and/or caregivers, MRI of the chest was performed (1.5 Tesla scanner; Avanto; Siemens Medical Solutions, Erlangen, Germany). The study protocol included the following sequences: 1) ECG-gated steady state free precession localiser images in the three orthogonal planes; 2) T2-weighted BLADE sequence with periodically rotated overlapping parallel lines with enhanced reconstruction in axial and coronal orientations; and 3) T1-weighted volumetric interpolated breath-hold examination (VIBE) before and after injection of gadopentetate dimeglumine (Magnevist; Bayer, Leverkusen, Germany). Lung morphometry (bronchiectasis, airway thickening, mucus plugging, parenchyma and trapped air) was quantified using the previously published CF-MRI scoring method [7, 8]. CF-MRI is an adapted version of the Brody score for MRI. Each lung lobe was scored independently, and the lingula was evaluated as a sixth lobe. Scores were expressed as a percentage of the maximum score. MBW to determine LCI was performed using sulfur hexafluoride (SF6) and a mass spectrometry-based apparatus (AMIS 2000; Innovision), as previously described [9]. Spirometry measures were analysed as percent predicted. MRI, followed by MBW and spirometry, was performed within 48 h of admission and after 12 days (range 9–16 days) of intravenous antibiotics for aPEs, respectively.

The study population was summarised using parametric methods for normally distributed data and nonparametric methods for skewed data where necessary. Comparisons before and after treatment were made using paired t-tests. Correlations between MRI and LCI outcomes at pre- and post-treatment time points, as well as correlations between the changes in outcomes, were assessed using Pearson's correlation coefficient.

In total, 13 patients (seven male, six female) underwent MRI before and after antibiotic treatment for aPE. Mean age of the study participants was 13.5 years (range 7.8–17.4 years). Mean±sd forced expiratory volume in 1 second (FEV1) was 67±16% before treatment, and increased to 74±14% after treatment (Δ7%, 95% CI 2–12%; p=0.01). Improvement was also seen for forced vital capacity (FVC) (p=0.04), FEV1/FVC (p=0.05) and forced expiratory flows at mid lung volumes (FEF25–75) (p=0.05). CF-MRI scores before and after treatment are given in table 1.

View this table:
  • View inline
  • View popup
TABLE 1

Cystic fibrosis magnetic resonance imaging scores before and after antibiotic treatment

CF-MRI scores improved significantly for mucus plugging (Δ-3.5, 95% CI −5.4 to −1.5; p=0.002) and air trapping (Δ-2.5, 95% CI −4.7 to −0.3; p=0.03), whereas no significant changes were seen for bronchiectasis (p=0.96), airway thickening (p=0.27), parenchyma (p=0.49) or total lung score (p=0.09).

Of the 13 patients who underwent MRI, eight had research-quality MBW measured before and after treatment. Mean±sd LCI score was 12.4±2.3 before treatment, and did not change with treatment (Δ-0.2, 95% CI −1.1 to 0.7; p=0.59). LCI before treatment was positively correlated with CF-MRI total lung score (r=0.64; p=0.06), mucus plugging score (r=0.72; p=0.03) and bronchiectasis score (r=0.70; p=0.04). However, there was an inverse correlation between changes in LCI and changes in CF-MRI total lung score (r=−0.85; p<0.01). Significant negative correlations suggested worsening of LCI (increase in LCI) with improvement in mucus plugging (r=−0.74; p=0.04) and air trapping (r=−0.79; p=0.02) after therapy (decrease in CF-MRI scores) (figure 1). There was no correlation between changes in MRI scores and changes in spirometry with therapy.

FIGURE 1
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1

Correlations between change in Lung Clearance Index (LCI) and changes in cystic fibrosis magnetic resonance imaging scores from pre- to post-treatment for acute pulmonary exacerbations. Significant negative correlations suggested worsening of LCI (increase in LCI) with improving mucus plugging and air trapping with therapy.

Consistent with previous studies, MRI can be used to quantify lung disease severity in children with CF, and measures of lung function by LCI correlated with CF-MRI scores at the time of aPE. Interestingly, there was considerable individual variability in response to treatment in both CF-MRI scores and LCI. However, in this study, CF-MRI scoring of improved mucus plugging and trapped air following treatment of aPE correlated with worsening LCI. This observation may be best explained by recruitment of poorly ventilated areas of the lung through improvement of mucus plugging with treatment, leading to worsening in LCI. This is consistent with the heterogeneous responses in LCI during treatment of pulmonary exacerbations in older children, which we reported previously [5]. Interestingly, a recent study in children with CF found a more consistent pattern of improvement in LCI with treatment of aPE [4]. Their study included younger children with better pulmonary function and therefore probably less structural lung damage, for whom the net effect of reducing mucus plugging is more likely to improve ventilation homogeneity. While other factors than age and disease severity may contribute to the discrepant results in the two studies, these data would support the concept that LCI as a measure of treatment response may be less informative in individuals with significant airflow obstruction compared with those with early airway disease, as previously suggested [10].

A limitation of our study is the relatively small sample size of patients who had both MRI and LCI measurements performed before and after treatment for aPE. Our findings therefore need to be interpreted with caution and confirmed in a larger population. Further studies are also needed to clarify the role of MBW and chest imaging techniques such as MRI for monitoring treatment responses other than those to antibiotics for aPEs in patients with CF and moderate to severe lung disease.

Disclosures

Supplementary Material

F. Ratjen ERJ-00244-2017_Ratjen

H.A.W.M. Tiddens ERJ-00244-2017_Tiddens

Footnotes

  • Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com

  • Received February 2, 2017.
  • Accepted May 29, 2017.
  • Copyright ©ERS 2017

References

  1. ↵
    1. Stanojevic S,
    2. McDonald A,
    3. Waters V
    , et al. Effect of pulmonary exacerbations treated with oral antibiotics on clinical outcomes in cystic fibrosis. Thorax 2017; 72: 327–332.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Waters V,
    2. Stanojevic S,
    3. Ratjen F
    . Special considerations for the treatment of pulmonary exacerbations in children with cystic fibrosis. Expert Rev Respir Med 2016; 10: 1221–1228.
    OpenUrl
  3. ↵
    1. Stanojevic S,
    2. Davis SD,
    3. Retsch-Bogart G
    , et al. Progression of lung disease in preschool patients with cystic fibrosis. Am J Respir Crit Care Med 2017; 195: 1216–1225.
    OpenUrl
  4. ↵
    1. Stahl M,
    2. Wielpütz MO,
    3. Graeber SY
    , et al. Comparison of lung clearance index and magnetic resonance imaging for assessment of lung disease in children with cystic fibrosis. Am J Respir Crit Care Med 2017; 195: 349–359.
    OpenUrl
  5. ↵
    1. Sonneveld N,
    2. Stanojevic S,
    3. Amin R
    , et al. Lung clearance index in cystic fibrosis subjects treated for pulmonary exacerbations. Eur Respir J 2015; 46: 1055–1064.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Wielpütz MO,
    2. Puderbach M,
    3. Kopp-Schneider A
    , et al. Magnetic resonance imaging detects changes in structure and perfusion, and response to therapy in early cystic fibrosis lung disease. Am J Respir Crit Care Med 2014; 189: 956–965.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Tepper LA,
    2. Ciet P,
    3. Caudri D
    , et al. Validating chest MRI to detect and monitor cystic fibrosis lung disease in a pediatric cohort. Pediatr Pulmonol 2016; 51: 34–41.
    OpenUrl
  8. ↵
    1. Ciet P,
    2. Serra G,
    3. Bertolo S
    , et al. Assessment of CF lung disease using motion corrected PROPELLER MRI: a comparison with CT. Eur Radiol 2016; 26: 780–787.
    OpenUrl
  9. ↵
    1. Amin R,
    2. Subbarao P,
    3. Lou W
    , et al. The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis. Eur Respir J 2011; 37: 806–812.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Horsley A
    . Lung clearance index in the assessment of airways disease. Respir Med 2009; 103: 793–799.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
View this article with LENS
Vol 50 Issue 2 Table of Contents
European Respiratory Journal: 50 (2)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Changes in magnetic resonance imaging scores and ventilation inhomogeneity in children with cystic fibrosis pulmonary exacerbations
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Changes in magnetic resonance imaging scores and ventilation inhomogeneity in children with cystic fibrosis pulmonary exacerbations
Hartmut Grasemann, Pierluigi Ciet, Reshma Amin, Nancy McDonald, Michelle Klingel, Harm A.W.M. Tiddens, Felix Ratjen, Lars Grosse-Wortmann
European Respiratory Journal Aug 2017, 50 (2) 1700244; DOI: 10.1183/13993003.00244-2017

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Changes in magnetic resonance imaging scores and ventilation inhomogeneity in children with cystic fibrosis pulmonary exacerbations
Hartmut Grasemann, Pierluigi Ciet, Reshma Amin, Nancy McDonald, Michelle Klingel, Harm A.W.M. Tiddens, Felix Ratjen, Lars Grosse-Wortmann
European Respiratory Journal Aug 2017, 50 (2) 1700244; DOI: 10.1183/13993003.00244-2017
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Disclosures
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • CF and non-CF bronchiectasis
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Agora

  • Balancing the risks and benefits of in-circuit bacterial filters
  • Polyurethane foam degradation in CPAP devices for sleep apnoea
  • Rifapentine access in Europe: concerns over key TB treatment
Show more Agora

Research letters

  • Polyurethane foam degradation in CPAP devices for sleep apnoea
  • P. aeruginosa membrane vesicles cause endothelial barrier failure
  • Mortality after admission with pneumonia higher than after admission with COPD exacerbation
Show more Research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society